仙味保金方治疗过敏性支气管哮喘的代谢组学研究
|
摘要
目的：
在建立家兔过敏性支气管哮喘模型的基础上,通过动物实验,引入代谢组学,确定与过敏性支气管哮喘相关联的有意义代谢产物,完善仙味保金方治疗过敏性支气管哮喘机理的研究方法,探索过敏性支气管哮喘动物模型代谢物组变化研究的新模式。
方法：
将家兔适应性饲养7天无异常后,模型组家兔和仙味保金方组家兔予10%卵蛋白(OVA)生理盐水溶液腹腔注射,剂量为1.2ml/kg,对照组家兔予等剂量生理盐水腹腔注射。每只家兔均注射一次。
14天后,对模型组、仙味保金方组家兔用1%0VA生理盐水溶液雾化激发；对照组用生理盐水雾化激发。连续雾化7日,每日一次,每次反复操作直至家兔出现腹肌抽搐、烦躁、唇鼻紫绀、二便失禁等表现。
雾化激发结束后第四天进行灌胃治疗,考虑到中药复方药效缓和但药效持久的特点,共给药3天。根据人与动物体表面积换算公式计算得到每只家兔每日的灌胃量为：0.35g药粉。具体灌胃操作如下：
第一步：先将0.35g药粉用温开水溶解定容至20ml药液,每只家兔20ml药液。
第二步：将家兔固定于兔盒内,经灌胃管注入20ml药液。(对照组与模型组家兔则以同样方法注入等剂量生理盐水。)
雾化激发结束后采取家兔耳缘静脉血、支气管肺泡灌洗液标本,用于嗜酸性粒细胞计数检测；灌胃治疗结束后采取家兔耳缘静脉血、支气管肺泡灌洗液和尿液标本,用于代谢组学检测。嗜酸性粒细胞计数统计分析应用SASV8软件,经方差齐性检验及正态性检验后,采用wilcoxon秩和检验,计量资料采用x±s表示；代谢产物统计分析采用单因素方差分析,计量资料采用x±s表示。
结果：
1.血清和支气管肺泡灌洗液嗜酸性粒细胞计数统计分析结果：在模型组计数与对照组相比均呈高表达(P<0.05)。
2.家兔血清样本代谢产物统计学分析结果：
异柠檬酸：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；果糖：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；葡萄糖酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；6-脱氧吡喃甘露糖：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；硬脂酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；半乳糖醛酸：对照组与模型组有差别(P<0.05),模型组与仙味保金方组无差别(P>0.05)。3.家兔支气管肺泡灌洗液样本代谢产物统计学分析结果：
甘氨酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；天冬氨酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；十四酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；半乳糖：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)。4.家兔尿液样本代谢产物统计学分析结果：
对羟基苯乙酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；木糖醇：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；3,5-二羟基苯甲酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；硬脂酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)
结论：
1.卵蛋白致敏新西兰家兔可成功建立过敏性支气管哮喘模型。
2.支气管肺泡灌洗液样本代谢产物中的甘氨酸、天冬氨酸、十四酸、半乳糖含量在模型组升高,说明与过敏性支气管哮喘病理变化有关。
3.支气管肺泡灌洗液样本代谢产物中的甘氨酸、天冬氨酸、十四酸、半乳糖含量在仙味保金方组的含量比模型组明显降低,说明仙味保金方具有修复代谢网络的作用。
4.血清样本代谢产物中的异柠檬酸、半乳糖醛酸、果糖、6-脱氧吡喃甘露糖在模型组含量改变,说明这些产物与过敏性支气管哮喘具有相关性。
5.血清样本代谢产物中的异柠檬酸、果糖、葡萄糖酸、硬脂酸、6-脱氧吡喃甘露糖含量在仙味保金方组发生变化,说明这些产物与仙味保金方中药成分发挥作用有关。
6.尿液样本代谢产物中的硬脂酸在模型组含量改变,说明与过敏性支气管哮喘具有相关性。
7.尿液样本代谢产物中的对羟基苯乙酸、木糖醇、3,5-二羟基苯甲酸和硬脂酸在仙味保金方组含量改变,说明这些产物与仙味保金方中药成分发挥作用有关。
Objective:
We confirm significative metabolic product related allergic bronchial asthma by metabolomics based on New Zealand rabbits asthma model.The objective is consummate the research method of the asthma's mechanism that xianweibaojin medication treating and exploring the new pattern of the reaserch in asthma model's metabolites group variation.
Method:
After 7 days with New Zealand Rabbits by adaptive breeding we give model group and treatment group rabbits 10% Ovalbumin(1.2ml/kg) by Celiac injecting. Normal group rabbits are given equivalent doses of physiological saline.Every rabbit is injected one time.
After 14 days we atomize model group and treatment group rabbits with 1% OVA solution by physiological saline. Normal group rabbits is atomized with physiological saline.We can't stop atomizing until rabbits express abdominal muscle twitching, fidgety, nose and lips cyanosis, urinary and fecal incontinence. The atomization lasting 7 days and 1 time everyday.
The fuorth day after atomizing we use irrigation stomach method to treat asthma rabbits.We determine 3 days to irrigate stomach because of the characteristics of the moderated and lasting efficacy of Chinese medicine compound. According to the conversion formula with people to animal we get the powder quantity of irrigation stomach is 0.35g.The specific operation:
1.We give treatment group rabbits 15ml solution that containing 0.35g powder and 14.65ml warm water.
2. Fixing the treatment group rabbits in the Rabbit box,then injecting the 15ml solution through gastric tube. (Normal group and model group rabbits are given the same dose physiological saline by the same method.)
After irrigating stomach we gather Venous blood, bronchial alveolar lavage fluid and urine to detect eosinophil and metabolic product.We choose SASV8 software to analyse eosinophil count by wilcoxon and to analyse metabolic product by Oneway ANOVA.The measurement data are expressed by x±s.
Result:
1.The eosinophil count of blood serum and bronchial alveolar lavage fluid in model group are higher than normal group (P<0.05).
2. The metabolic product of blood serum sample's statistics analysis resaults: isocitric acid:Compared with the model group, the isocitric acid expression was significantly higher than normal group (P<0.05).
fructose:Compared with the model group, the fructose expression was significantly lower than normal group (P<0.05); Compared with the model group, the fructose expression was significantly lower than treatment group (P<0.05)
glucose sour:Compared with the model group, the glucose sour expression was significantly lower than normal group (P<0.05); Compared with the model group, the glucose sour expression was significantly lower than treatment group (P<0.05)
6-deoxidizing pyranoid mannose:Compared with the model group, the 6-deoxidizing pyranoid mannose expression was significantly lower than normal group (P<0.05).
stearic acid:Compared with the treatment group, the stearic acid expression was significantly lower than model group (P<0.05); Compared with the normal group, the stearic acid expression was no difference to model group (P>0.05).
half of lactose hyaluronic acid:Compared with the model group, the half of lactose hyaluronic acid expression was significantly higher than normal group (P<0.05); Compared with the treatment group, the half of lactose hyaluronic acid expression was no difference to model group (P>0.05).
3. The metabolic product of bronchial alveolar lavage fluid sample's statistics analysis resaults:
glycine:Compared with the model group, the glycine expression was significantly higher than normal group (P<0.05); Compared with the model group, the glycine expression was significantly higher than treatment group (P<0.05)
L-aspartic acid:Compared with the model group, the L-aspartic acid expression was significantly higher than normal group (P<0.05); Compared with the model group, the L-aspartic acid expression was significantly higher than treatment group (P<0.05).
tetradecaoic acid:Compared with the model group, the tetradecaoic acid expression was significantly higher than normal group (P<0.05); Compared with the model group, the tetradecaoic acid expression was significantly higher than treatment group (P<0.05)
half of lactose::Compared with the model group, the half of lactose expression was significantly higher than normal group (P<0.05); Compared with the model group, the half of lactose expression was significantly higher than treatment group (P<0.05)
4. The metabolic product of urine sample's statistics analysis resaults:
serine:Compared with the normal group, the serine expression was no difference to model group (P>0.05).
hydroxyl ethyl benzene:Compared with the treatment group, the hydroxyl ethyl benzene expression was significantly lower than model group(P<0.05); Compared with the model group, the hydroxyl ethyl benzene expression was no difference to normal group (P>0.05).
xylitol:Compared with the treatment group, the xylitol expression was significantly lower than model group (P<0.05); Compared with the model group, the xylitol expression was no difference to normal group (P>0.05).
5-bis hydroxy benzoic acid:Compared with the treatment group, the5-bis hydroxy benzoic acid expression was significantly lower than model group (P<0.05); Compared with the model group, the5-bis hydroxy benzoic acid expression was no difference to normal group (P>0.05).
stearic acid:Compared with the treatment group, the stearic acid expression was significantly lower than model group (P<0.05); Compared with the normal group, the stearic acid expression was significantly higher than model group (P<0.05).
Conclusion:
1.We Simulate New Zealand Rabbits allergic allergic bronchial asthma model with injecting ovalbumin in celiac successfully.
2.The content of glycine, L-aspartic acid, tetradecaoic acid and half of lactose of bronchial alveolar lavage fluid in the model group higher than normal group.We confirm these four metabolic products have the close correlation to allergic bronchial asthma.
3.These four different metabolic products' content of bronchial alveolar lavage fluid in the treatment group below the model group obviously.The treatment group's content is close to normal group. The description above explain that xianweibaojin medication can repair the Metabolic network and recovery allergic bronchial asthma by specific change.
4.The content of isocitric acid, fructose,6-deoxidizing pyranoid mannose.half of lactose hyaluronic acid of blood serum are changed when the rabbits catch allergic bronchial asthma. We confirm these four metabolic products have the close correlation to allergic bronchial asthma.
5.The content of isocitric acid and stearic acid of blood serum in the treatment group are lower than the model group. The content of fructose, glucose sour and 6-deoxidizing pyranoid mannose of blood serum in the treatment group are higher than the model group. We confirm these five metabolic products have the close correlation to xianweibaojin compound medicine.
6. The content of stearic acid of urine in the model group are lower than the normal group. We confirm stearic acid have the close correlation to allergic bronchial asthma.
7. The content of serine, hydroxyl ethyl benzene, xylitol and 5-bis hydroxy benzoic acid of urine in the treatment group are lower than the model group. We confirm these five metabolic products have the close correlation to xianweibaojin compound medicine.
在建立家兔过敏性支气管哮喘模型的基础上,通过动物实验,引入代谢组学,确定与过敏性支气管哮喘相关联的有意义代谢产物,完善仙味保金方治疗过敏性支气管哮喘机理的研究方法,探索过敏性支气管哮喘动物模型代谢物组变化研究的新模式。
方法：
将家兔适应性饲养7天无异常后,模型组家兔和仙味保金方组家兔予10%卵蛋白(OVA)生理盐水溶液腹腔注射,剂量为1.2ml/kg,对照组家兔予等剂量生理盐水腹腔注射。每只家兔均注射一次。
14天后,对模型组、仙味保金方组家兔用1%0VA生理盐水溶液雾化激发；对照组用生理盐水雾化激发。连续雾化7日,每日一次,每次反复操作直至家兔出现腹肌抽搐、烦躁、唇鼻紫绀、二便失禁等表现。
雾化激发结束后第四天进行灌胃治疗,考虑到中药复方药效缓和但药效持久的特点,共给药3天。根据人与动物体表面积换算公式计算得到每只家兔每日的灌胃量为：0.35g药粉。具体灌胃操作如下：
第一步：先将0.35g药粉用温开水溶解定容至20ml药液,每只家兔20ml药液。
第二步：将家兔固定于兔盒内,经灌胃管注入20ml药液。(对照组与模型组家兔则以同样方法注入等剂量生理盐水。)
雾化激发结束后采取家兔耳缘静脉血、支气管肺泡灌洗液标本,用于嗜酸性粒细胞计数检测；灌胃治疗结束后采取家兔耳缘静脉血、支气管肺泡灌洗液和尿液标本,用于代谢组学检测。嗜酸性粒细胞计数统计分析应用SASV8软件,经方差齐性检验及正态性检验后,采用wilcoxon秩和检验,计量资料采用x±s表示；代谢产物统计分析采用单因素方差分析,计量资料采用x±s表示。
结果：
1.血清和支气管肺泡灌洗液嗜酸性粒细胞计数统计分析结果：在模型组计数与对照组相比均呈高表达(P<0.05)。
2.家兔血清样本代谢产物统计学分析结果：
异柠檬酸：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；果糖：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；葡萄糖酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；6-脱氧吡喃甘露糖：对照组与模型组有差别(P<0.05),模型组与仙味保金方组有差别(P<0.05)；硬脂酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；半乳糖醛酸：对照组与模型组有差别(P<0.05),模型组与仙味保金方组无差别(P>0.05)。3.家兔支气管肺泡灌洗液样本代谢产物统计学分析结果：
甘氨酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；天冬氨酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；十四酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)；半乳糖：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)。4.家兔尿液样本代谢产物统计学分析结果：
对羟基苯乙酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；木糖醇：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；3,5-二羟基苯甲酸：对照组与模型组无差别(P>0.05),模型组与仙味保金方组有差别(P<0.05)；硬脂酸：对照组与模型组有差别(P<0.05)、模型组与仙味保金方组有差别(P<0.05)
结论：
1.卵蛋白致敏新西兰家兔可成功建立过敏性支气管哮喘模型。
2.支气管肺泡灌洗液样本代谢产物中的甘氨酸、天冬氨酸、十四酸、半乳糖含量在模型组升高,说明与过敏性支气管哮喘病理变化有关。
3.支气管肺泡灌洗液样本代谢产物中的甘氨酸、天冬氨酸、十四酸、半乳糖含量在仙味保金方组的含量比模型组明显降低,说明仙味保金方具有修复代谢网络的作用。
4.血清样本代谢产物中的异柠檬酸、半乳糖醛酸、果糖、6-脱氧吡喃甘露糖在模型组含量改变,说明这些产物与过敏性支气管哮喘具有相关性。
5.血清样本代谢产物中的异柠檬酸、果糖、葡萄糖酸、硬脂酸、6-脱氧吡喃甘露糖含量在仙味保金方组发生变化,说明这些产物与仙味保金方中药成分发挥作用有关。
6.尿液样本代谢产物中的硬脂酸在模型组含量改变,说明与过敏性支气管哮喘具有相关性。
7.尿液样本代谢产物中的对羟基苯乙酸、木糖醇、3,5-二羟基苯甲酸和硬脂酸在仙味保金方组含量改变,说明这些产物与仙味保金方中药成分发挥作用有关。
Objective:
We confirm significative metabolic product related allergic bronchial asthma by metabolomics based on New Zealand rabbits asthma model.The objective is consummate the research method of the asthma's mechanism that xianweibaojin medication treating and exploring the new pattern of the reaserch in asthma model's metabolites group variation.
Method:
After 7 days with New Zealand Rabbits by adaptive breeding we give model group and treatment group rabbits 10% Ovalbumin(1.2ml/kg) by Celiac injecting. Normal group rabbits are given equivalent doses of physiological saline.Every rabbit is injected one time.
After 14 days we atomize model group and treatment group rabbits with 1% OVA solution by physiological saline. Normal group rabbits is atomized with physiological saline.We can't stop atomizing until rabbits express abdominal muscle twitching, fidgety, nose and lips cyanosis, urinary and fecal incontinence. The atomization lasting 7 days and 1 time everyday.
The fuorth day after atomizing we use irrigation stomach method to treat asthma rabbits.We determine 3 days to irrigate stomach because of the characteristics of the moderated and lasting efficacy of Chinese medicine compound. According to the conversion formula with people to animal we get the powder quantity of irrigation stomach is 0.35g.The specific operation:
1.We give treatment group rabbits 15ml solution that containing 0.35g powder and 14.65ml warm water.
2. Fixing the treatment group rabbits in the Rabbit box,then injecting the 15ml solution through gastric tube. (Normal group and model group rabbits are given the same dose physiological saline by the same method.)
After irrigating stomach we gather Venous blood, bronchial alveolar lavage fluid and urine to detect eosinophil and metabolic product.We choose SASV8 software to analyse eosinophil count by wilcoxon and to analyse metabolic product by Oneway ANOVA.The measurement data are expressed by x±s.
Result:
1.The eosinophil count of blood serum and bronchial alveolar lavage fluid in model group are higher than normal group (P<0.05).
2. The metabolic product of blood serum sample's statistics analysis resaults: isocitric acid:Compared with the model group, the isocitric acid expression was significantly higher than normal group (P<0.05).
fructose:Compared with the model group, the fructose expression was significantly lower than normal group (P<0.05); Compared with the model group, the fructose expression was significantly lower than treatment group (P<0.05)
glucose sour:Compared with the model group, the glucose sour expression was significantly lower than normal group (P<0.05); Compared with the model group, the glucose sour expression was significantly lower than treatment group (P<0.05)
6-deoxidizing pyranoid mannose:Compared with the model group, the 6-deoxidizing pyranoid mannose expression was significantly lower than normal group (P<0.05).
stearic acid:Compared with the treatment group, the stearic acid expression was significantly lower than model group (P<0.05); Compared with the normal group, the stearic acid expression was no difference to model group (P>0.05).
half of lactose hyaluronic acid:Compared with the model group, the half of lactose hyaluronic acid expression was significantly higher than normal group (P<0.05); Compared with the treatment group, the half of lactose hyaluronic acid expression was no difference to model group (P>0.05).
3. The metabolic product of bronchial alveolar lavage fluid sample's statistics analysis resaults:
glycine:Compared with the model group, the glycine expression was significantly higher than normal group (P<0.05); Compared with the model group, the glycine expression was significantly higher than treatment group (P<0.05)
L-aspartic acid:Compared with the model group, the L-aspartic acid expression was significantly higher than normal group (P<0.05); Compared with the model group, the L-aspartic acid expression was significantly higher than treatment group (P<0.05).
tetradecaoic acid:Compared with the model group, the tetradecaoic acid expression was significantly higher than normal group (P<0.05); Compared with the model group, the tetradecaoic acid expression was significantly higher than treatment group (P<0.05)
half of lactose::Compared with the model group, the half of lactose expression was significantly higher than normal group (P<0.05); Compared with the model group, the half of lactose expression was significantly higher than treatment group (P<0.05)
4. The metabolic product of urine sample's statistics analysis resaults:
serine:Compared with the normal group, the serine expression was no difference to model group (P>0.05).
hydroxyl ethyl benzene:Compared with the treatment group, the hydroxyl ethyl benzene expression was significantly lower than model group(P<0.05); Compared with the model group, the hydroxyl ethyl benzene expression was no difference to normal group (P>0.05).
xylitol:Compared with the treatment group, the xylitol expression was significantly lower than model group (P<0.05); Compared with the model group, the xylitol expression was no difference to normal group (P>0.05).
5-bis hydroxy benzoic acid:Compared with the treatment group, the5-bis hydroxy benzoic acid expression was significantly lower than model group (P<0.05); Compared with the model group, the5-bis hydroxy benzoic acid expression was no difference to normal group (P>0.05).
stearic acid:Compared with the treatment group, the stearic acid expression was significantly lower than model group (P<0.05); Compared with the normal group, the stearic acid expression was significantly higher than model group (P<0.05).
Conclusion:
1.We Simulate New Zealand Rabbits allergic allergic bronchial asthma model with injecting ovalbumin in celiac successfully.
2.The content of glycine, L-aspartic acid, tetradecaoic acid and half of lactose of bronchial alveolar lavage fluid in the model group higher than normal group.We confirm these four metabolic products have the close correlation to allergic bronchial asthma.
3.These four different metabolic products' content of bronchial alveolar lavage fluid in the treatment group below the model group obviously.The treatment group's content is close to normal group. The description above explain that xianweibaojin medication can repair the Metabolic network and recovery allergic bronchial asthma by specific change.
4.The content of isocitric acid, fructose,6-deoxidizing pyranoid mannose.half of lactose hyaluronic acid of blood serum are changed when the rabbits catch allergic bronchial asthma. We confirm these four metabolic products have the close correlation to allergic bronchial asthma.
5.The content of isocitric acid and stearic acid of blood serum in the treatment group are lower than the model group. The content of fructose, glucose sour and 6-deoxidizing pyranoid mannose of blood serum in the treatment group are higher than the model group. We confirm these five metabolic products have the close correlation to xianweibaojin compound medicine.
6. The content of stearic acid of urine in the model group are lower than the normal group. We confirm stearic acid have the close correlation to allergic bronchial asthma.
7. The content of serine, hydroxyl ethyl benzene, xylitol and 5-bis hydroxy benzoic acid of urine in the treatment group are lower than the model group. We confirm these five metabolic products have the close correlation to xianweibaojin compound medicine.
引文
[1]宋·许叔微.普济本事方[M].上海：上海科学技术出版社,1959,39.
[2]清·沈金鳌.杂病源流犀烛[M].北京：中国中医药出版社,1994,22.
[3]清·林佩琴.类证治栽[M].上海：上海中医药大学出版社,1997,101.
[4]明·张景岳.景岳全书[M].北京：中国中医药出版社,2006,226.
[5]明·戴思恭.秘传证治要诀[M].北京：中国中医药出版社,1998,79.
[6]明·秦景明.症因脉治[M].上海：上海科学技术出版社,1990,145.
[7]清·叶天士.临证指南医案[M].北京：华夏出版社,1995,226-227.
[8]清·陈修园.时方妙用[M].福州：福建科学技术出版社,1986,49-50.
[9]清·何梦瑶.医碥[M].上海：上海科学技术出版社,1992,95.
[10]隋·巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社,1997,18-75.
[11]唐·王焘.外台秘要精华本[M].沈阳：辽宁科学技术出版社,1998,54-87.
[12]元·朱震亨.丹溪心法[M].北京：人民卫生出版社,2005,27-28.
[13]明·王肯堂.证治准绳[M]北京：人民卫生出版社,1991,99.
[14]清·唐容川.血证论[M].北京：中国中医药出版社,1996,147.
[15]汉·张仲景.金匮要略[M].北京：人民卫生出版社,2005,44.
[16]清·李用粹.证治汇补[M].上海：上海卫生出版社,1958,278.
[17]明·楼英.医学纲目[M].北京：中国中医药出版社,1996,604.
[18]明·李中梓.医宗必读[M].北京：中国中医药出版社,1 999,261.
[19]清·吴谦.医宗金鉴精选[M].北京：科学技术文献出版社,1996,53.
[20]元·朱丹溪.金匮钩玄[M].北京：人民卫生出版社,1980,15.
[21]清·陈梦雷.古今图书集成医部全录·诸疾(上)[M]北京：人民卫生出版社,1962,1394-1399.
[1]代晓光,陈晶,郭欣,等.化痰法治疗哮喘的研究现状及评价[J].中医药信息,2005,22(6)：7-9.
[2]冯新格.吴银根妙用药对治疗支气管哮喘[J].浙江中医杂志,1999,34(12)：507-508.
[3]王江.治疗哮喘浅谈[J].河南中医,2006,26(12)：32-33.
[4]赵宝林.哮喘病因病机及经方认识的探讨[J].中医药临床杂志,2006,1 8(1)：85-87.
[5]孙继铭.从内风论治支气管哮喘90例分析[J].实用中医内科杂志,2003,17(5)：414
[6]王鹏.中医哮病学[M].北京：中国医药科技出版社,2002,10.
[7]吴银根,于素霞,张惠勇,等.咳喘落治疗175例哮喘临床总结[J].上海中医药杂志,2000,34(9)：20.
[8]聂广.肺朝百脉及其临床意义[J].贵阳中医学院学报,1989,11(1)：7-8.
[9]洪广祥.支气管哮喘病科研思路方法刍议[J].江西中医药,1991,22(2)：11-14.
[10]刘莎,卢薇.浅谈支气管哮喘的中医药研究[J].光明中医,2009,24(1)：171.
[11]金小晶,张文博.张明德谈哮喘“夙根”[J].时珍国医国药,2002,13(12)：756.
[12]刘仁慧.哮喘缓解期治疗宜肺脾肾三脏并补[J].现代中西医结合杂志,2004,13(24)：3354.
[13]袁启福,汤淑兰.祛风平喘汤治疗儿童哮喘发作50例[J].湖南中医学院学报,1995,15(1)：24-25.
[14]张洪春,晁恩祥.疏风解痉法治疗过敏性支气管哮喘的临床研究[J].中国中医急症,1998,7(2)：54-60.
[15]于作洋.刘弼臣教授治疗小儿哮喘的经验[J].山西中医,1998,14(4)：6-7.
[16]熊耀,俞冰.哮喘临床研究进展[J].浙江中医学院学报,2001,25(3)：5-7.
[17]王长洪.董建华治疗哮喘的经验[J].辽宁中医杂志,1999,26(12)：531-532.
[18]张占伟,王春玲,王鹏,等.温阳化瘀法在治疗哮喘中的应用[J].中医药研究,2000,16(8)：55-57.
[19]毛玉燕.钱育寿治疗小儿哮喘的经验[J].河北中医,2000,22(3)：1-2.
[20]刘玉山,张爱华,王玉民.射干麻黄汤加味治疗小儿哮喘103例疗效观察[J].河北中医,2001,23(6)：4.
[21]张天嵩,吴红梅.吴银根温阳法分期治疗哮喘学术特色探析[J].中医函授通讯,1999,18(6)：3-5.
[22]张穗,张小鹰,赵前江.倪珠英论治小儿哮喘的经验[J].湖北中医学院院报,2000,2(2)：36.
[23]杨华萃,许尤佳.中西医结合治疗小儿哮喘的远期疗效观察[J].湖北中医杂志,2000,22(8)：17-18.
[24]廖世才.小儿哮喘活血化瘀法治疗体会[J].江西中医药,1997,28(6)：33-34.
[25]陈黎明,张俐.从瘀血论治哮喘机理探讨[J].国医论坛,1999,14(2)：17.
[26]王明明,汪受传.玉屏风散预防小儿哮喘临床效果及机理探讨[J].时珍国医国药,2001,12(5)：457-458.
[27]杨定保.小儿哮喘辨治三法[J].湖北中医杂志,2001,23(4)：21.
[28]魏伟,吴成.中医对哮喘病因病机及发作期冷热分型认识初探[J].现代中西医结合杂志,2004,13(11)：1444.
[29]王爱明.中西医结合防治小儿哮喘64例疗效观察[J].江苏中医,2000,21(3)：22-23.
[30]罗玉华.小儿哮喘的中医辨证治疗[J].四川中医,2002,20(1)：17.
[31]张成博.哮喘病分期及治疗构想[J].山东中医杂志,2005,24(9)：519-520.
[32]田德禄主编.中医内科学[M].北京：人民卫生出版社,2002,69-72.
[1]张洪春,晁恩祥.疏风解痉法治疗过敏性支气管哮喘的临床研究.中国中医急症,1998,7(2)：54-58.
[2]闫建纯.中药颗粒剂麻杏祛风定喘方治疗幼儿哮喘[J].湖北中医杂志,2006,28(8)：26.
[3]付伟.中药治疗支气管哮喘50例体会[J].哈尔滨医药,2005,25(3)：56.
[4]武维屏.调肝理肺法治疗哮喘174例小结[J].北京中医学院学报,1990,13(4)：55.
[5]董振华,季元,范爱平.祝谌予治疗哮喘的经验[J].浙江中医杂志,1994,29(1)：19.
[6]武振东,潘成轩,秦立云.血府逐瘀汤为主治疗支气管哮喘61例观察[J].河南中医,2000,20(6)：43.
[7]李庆林.桃红四物汤加减治疗哮喘31例[J].河南中医,2005,25(3)：66.
[8]陈茂业.金芪固本汤治疗支气管哮喘缓解期46例临床观察[J].云南中医中药杂志,2007,28(6)： 24.
[9]单昌涛.加味补中益气汤治疗支气管哮喘缓解期的临床观察[J].河北中医,2005,27(8)：604.
[10]黎经兰.补肾纳气法治疗小儿支气管哮喘38例[J].中医研究,2005,18(1)：39-40.
[11]王德玉,柴可群.咳喘从肝论治[J].浙江中医学院学报,1993，17(4)：10.
[12]王利,车戬,朴龙华.调肝理肺汤治疗支气管哮喘急性发作期的临床研究[J].辽宁中医杂志,2003,30(6)：465-466.
[13]史锁芳.曹世宏治支气管哮喘经验[J].江西中医药,1998,29(6)：76.
[14]刘自力,张庆荣,吴兆利.论脾虚为哮喘宿根[J].中医药学刊,2006,24(2)：294-295.
[15]周虎.和胃降逆法治疗夜间哮喘临床观察[J].中医杂志,1993,34(6)：359.
[16]蔡润清,吴伟平.支气管哮喘缓解期从脾论治80例临床探讨[J].贵阳中医学院学报,2007,29(2)：29-30.
[17]张洁,施光其.黄芪六君子汤治疗哮喘缓解期85例临床观察[J].山东中医杂志,2004,23(4)：204-205.
[18]翟乃会,武翠风.通腑泄肺法治疗顽固性哮喘53例[J].陕西中医,1999,20(10)：466.
[19]李家榕.审证求因治咳喘一张鸿祥经验谈[J].上海中医药杂志,1996,30(4)： 24.
[20]苏惠萍.通腑法治疗哮喘发作期的临床应用[J].北京中医药大学学报,1995,18(5)：64.
[21]龙学明,唐耀平,黄洁,等.补肺片对支气管哮喘缓解期患者CD4+、CD8+及IgE影响的临床研究[J].新中医,2007,39(5)：27-28.
[22]王晓玫,李忠学.固金止喘汤治疗支气管哮喘缓解期35例的疗效分析[J].中华实用中西医杂志,2006,19(6)：661-662.
[23]刘勤建.玉屏风散合参蛤散治疗缓解期哮喘疗效观察[J].中国中医基础医学杂志,2002,8(12)：45-47.
[24]张锦珠,王健民.补肺益肾汤治疗支气管哮喘32例[J].陕西中医,1995,16(10)：439.
[25]吴彬,俞建,王营,等.补肾中药对哮喘缓解期患儿Th1/Th2平衡的影响[J].中国中西医结合杂志,2007,27(4)：120-122.
[26]刘小虹,廖慧丽.补肾祛邪法治疗哮喘的临床研究[J].中医药学刊,2002,20(5)：697-700.
[27]李容娟,固肾纳气汤治疗肾虚型哮喘缓解期42例疗效观察[J].右江民族医学院学报,1997,19(3)：449-500.
[28]刘贵云,向华林,米仁贤,等.治喘伏帖灵治疗小儿哮喘139例疗效观察[J].中医杂志,1999,40(8)：474.
[29]刘霞秋,徐京生,崔锐.交九散贴敷治疗支气管哮喘的临床观察[J].中国中西医结合杂志,1996,16(5)：297.
[30]姜静,尚宁,范欣生.中药辛夷雾化吸入治疗支气管哮喘[J].临床肺科杂志,2001,6(2)：17.
[31]张莉,周勇,王旭丹,等.芩夏止哮颗粒对哮喘小鼠T细胞活化和细胞因子水平的影响[J].中药药理与临床,2002,18(1)：21-23.
[32]倪力强,张宁霞,童瑶,等.小青龙汤对哮喘大鼠Thl/Th2型细胞因子水平的影响[J].辽宁中医杂志,2003,30(9)：703-704.
[33]谭素娟,艾华.射干麻黄汤化裁方抗过敏性支气管哮喘的实验研究[J].中医杂志,2000,41(5)：282.
[34]谢瑾玉,董竞成.补肾益气中药仙灵脾和黄芪对哮喘大鼠TNF-α和NF-κB的影响[J].中国中西医结合杂志,2006,26(8)：723-724.
[35]张弦,王强,孙增涛.补肺方对缓解期哮喘豚鼠气道重塑作用机制的研究[J].江西中医学院学报,2009,21(2)：57-58.
[36]刘小虹,廖慧丽.射麻止喘液对哮喘模型大鼠环核甘酸变化的影响[J].广东中医药大 学学报,2001,18(4)：339-340.
[37]赵琰,屈会化,张晗睿,等.加味三拗汤平喘作用及对肺功能影响的实验研究[J].北京中医药大学学报,2009,32(1)：21-24.
[38]黄乐珊,郑师明.截喘汤对哮喘模型小鼠外周血浆IL-5、TNF-α及Eotaxin的影响[J].中国药房,2007,18(15)：1134-1135.
[39]吴银根,王宏长,张惠永,等.温阳抗寒合剂对实验性哮喘动物模型的研究[J].中国中医基础杂志,1996,2(2)：22.
[40]崔红生,黄启福,武维屏,等.哮喘宁煎剂对哮喘豚鼠模型气道EOS浸润的影响[J].中华结核和呼吸杂志,1992,22(8)：495.
[41]王力宁,李伟伟,李伟芳,等.六味地黄丸协同必可酮对致敏豚鼠气道反应性及血嗜酸细胞的影响[J].广西中医药,2001,24(6)：51.
[42]李寅超,赵宜红,薛敬礼,等.辛夷挥发油对哮喘豚鼠嗜酸性粒细胞影响的实验研究[J].现代预防医学,2006,33(8)：1338-1341.
[43]邬继红,马惠芳,袁红,等.不同针刺频度对致敏豚鼠血清总IgE影响的实验研究[J].针刺研究,2006：31(3)：153-155.
[44]司小兵,陈淑彦.“咳喘宁”贴膏对支气管哮喘模型大鼠血清IL-8及TNF-α的影响[J].甘肃中医学院学报,2006,23(6)：6-7.
[45]刘世琼,张全爱.咳喘灵贴膏贴敷穴位治疗豚鼠哮喘的实验研究[J].中医药学刊,2004,22(4)：620-621.
[1]董滟,雷敏.中医药治疗支气管哮喘的优势评析[J].四川中医,2006,24(12)：21-23.
[2]武维屏.激素依赖性哮喘的中医治疗浅述[J].北京中医药大学学报,1997,20(1)： 58.
[3]许德金,叶丽红.活血化瘀药防治支气管哮喘的研究进展[J].微循环技术杂志,1996,3163.
[4]方文贤.医用中药药理学[M].北京：人民卫生出版社,1998,18.
[1]王建华,张永祥,周文霞主编.中药药理与临床研究进展[M].北京：人民卫生出版社,2006：386.
[2]陈慧梅.代谢组学及研究方法和应用[J].肾脏病与透析肾移植杂志,2005,14(1)：59-63.
[3]Gennan JB,Bauman DE,Burrrin DG,et al.Metabolomics in the opening decade of the 21st century:building the roads to individualiazed health[J].Jnutn,2004,134 (10):27-29.
[4]邓海山,段金廒,尚尔鑫,等.代谢组学的研究现状及其在方剂量效关系中的应用[J].国际药学研兖杂志,2009,36(3)：199.
[5]魏聪.代谢组学及其在中医药现代化研究中的应用进展[J].疑难病杂志,2009,(8)11：698.
[6]许国旺,路鑫,杨胜利.代谢组学研究进展[J].中国医学科学院学报.2007,29(6)：701-711.
[7]罗和古,丁杰,岳广欣,等.大鼠肝郁脾虚证的代谢组学研究[J].中西医结合学报,2007,5(3)：307-313.
[8]高岗,杨根金,娄子洋.肾虚证大鼠尿液的核磁共振谱代谢组学研究[J]。第二军医大学学报,2009,30(5)：5665-5668.
[9]刘树民,卢芳,王喜军,等.基于代谢组学的热病证候模型评价方法研究[J].中国药理学通报,2009,25(4)：549-551.
[10]Chen MJ, Zhao LP.Jia W. Metahonomicon study on the biochemical profiles of hydroeoaisone-inducedmodel animal model[J].Journal of Proteme Research,2005,4(6): 2391-2396.
[11]严蓓,阿基业,郝海平,等.心血瘀阻与气阴两虚证心肌缺血大鼠模型的代谢组学表征与辨识[J].中国科学c辑：生命科学,2008,38(12)：1143-1151.
[12]王广基,阿基业,严培,等.代谢组学研究冠心病中医分型的体内物质基础[J].世界科学技术-中医药现代化,2009,11(1)：127-133.
[13]郑海生,蒋健,贾伟,等.慢性心力衰竭肾阳虚患者代谢组学研究[J].中华中医药杂志,2010,25(2)：198-201.
[14]吕爱平.类风湿性关节炎中医证候分类的系统生物学基础[J].世界科学技术-中医药现代化,2007,9(1)：94-97.
[15]董飞侠,黄迪,何立群,等.Ⅲ期慢性肾病肾阳虚证患者尿液代谢组学特征的研究[J].中华中医药杂志,2008,23(12)：1109-1113.
[16]杨松滨,李听,苏明明,等.膝骨关节炎患者尿液代谢谱与中医证候的相关性研究[J].上海中医药大学学报,2009,23(1)：33-37.
[17]王喜军,孙文军,孙晖,等.CCI诱导大鼠肝损伤模型的代谢组学及茵陈蒿汤的干预作用研究[J].世界科学技术—中医药现代化,2006,8(6)：101-106.
[18]黄玉荣,魏广力,龙红.钩藤多动合剂的药效作用及用代谢组学方法研究其生化机制[J].中草药,2005,36(3)：398-402.
[19]周明眉,刘平,贾伟.基于代谢网络变化的中药整体效应评价方法研究[J].世界科学技术-中医药现代化,2006,8(6)：113-119.
[20]邱云平,苏明明,吴大正,等.金复康对大鼠大肠癌癌前病变的改善作用及尿液代谢物研究[J].中国中药杂志,2008,33(22)：2653-2657.
[21]Li FM,Lu XM,Liu HP,et al.A pharmaco-metabonomic study basis and metabolic effects of Epimedium brevleomum Maxim.on hydroeortisone-induced rat using UPLC-MS[J]. Biomed Chromatogr,2007,21(4):397-405.
[22]蒋宁,周文霞,张永样.应用代谢组学方法研究比较六味及八味地黄汤的作用机理[J].中药药理与临床,2007,23(5)：45.
[23]Minjun Chen,Liping Zhao,Weijia,et al.Metabonomic study on the biochemical profile of a hydrocortisone induced animal model[J].J Proteome Res,2005,4(6):2391-2396.
[24]陆益红,王广基,黄青,等.自发性高血压大鼠血浆代谢组学研究及人参总皂苷作用机制初探[J].中国天然药物,2007,11(6)：443-447.
[25]薛骞.代谢组学技术：中医药发展的重大契机[J].中华中医药学刊,2008,26(1)：176-177.
[26]赵剑宇,颜贤忠,彭双清.利用代谢组学技术研究中药关木通的肾毒性作用[J].世界科学技术一中医药现代化,2007,9(5)：54.
[27]李建新,华嘉,何翠翠.中药毒性的代谢组学研究(Ⅰ)雷公藤甲素的肾脏毒性[J].亚太 传统医药,2007,3(7)：4145.
[28]张晓字,吴惠丰,裴奉套,等.核磁共振技术结合模式识别对中药马兜铃酸哑急性生化效应的研究[J].高等学校化学学报,2005,26(6)：991-996.
[29]蒋怀周,鲍远程.代谢组学应用于中医药研究的思考[J].中医药学报,2010,38(4)：63-67.
[30]曾瑞峰,李俊.代谢组学方法及其在中医药研究的现状与展望[J].中国中医药现代远程教育,2010,8(17)：205-206.
[1]清·雷丰.时病论[M].北京：人民卫生出版社,2008.136.
[2]周悦.中医药治疗哮喘的优势浅谈[J].江西中医药,2009,4 0(320)：9-10.
[1]刘素芝,刘玉丽,曹国龙,等.哮喘动物模型免疫炎症反应发生验证的要点[J].中国组织工程研究与临床康复,2007,2(29)：5814.
[2]何会霞,李自红.支气管哮喘实验动物模型的研究进展[J].中国老年学杂志,2008,23(10)：2074.
[3]颜晓燕,董志远.哮喘动物模型研究现状[J].成都医学院学报,2007,2(2)：157.
[4]Obiefuna P. C. M, Batra V. K, Nadeem A, Borron Pet al.Novel Adenosine Receptor Antagonist,L-97-1[3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-e thyl}-l-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma[J]. Mustafa J Pharmacol Exp Ther.2005 October 315(1): 329-336.
[5]刘学.血液中嗜酸性粒细胞与气道高反应性关系分析研究[J],安庆医学,2004,25(3)：12-13.
[6]唐美仪,毛新,姜运良.新生家兔白细胞系统数量和形态的日龄相关性变化[J].曲阜师范大学学报,1991,17(3)：66-70.
[7]中华医学会呼吸病学分会.支气管肺泡灌洗液细胞学检测技术规范(草案)[J].中华结核和呼吸杂志,2002,25(7)：390-391.
[8]Hall JC. Glycine. J Parenter Enterol Nutri,1998,22(6):393-398.
[9]Grotz MR, Pape HC, Van Griensven M, et al. Glycine reduces thein flammatory response and organ damage in a two-hit sepsis modelin rats. Shock,2001,16:116-121.
[10]Legendre P.The glycinergic inhibitory synapse[J].Cell Mol Life Sci,2001,58(5-6):76-93.
[11]冯端兴,叶贤伟,张湘燕,等.132—肾上腺素能受体基因多态性与支气管哮喘的研究[J].现代临床医学生物工程学杂志,2004,10(1)：5-7.
[12]刘超,郭贵龙,姚榛祥.甘氨酸对腹腔感染小鼠急性肺损伤的作用[J].山西临床医药杂志,2001,10(5)：331-333.
[2]清·沈金鳌.杂病源流犀烛[M].北京：中国中医药出版社,1994,22.
[3]清·林佩琴.类证治栽[M].上海：上海中医药大学出版社,1997,101.
[4]明·张景岳.景岳全书[M].北京：中国中医药出版社,2006,226.
[5]明·戴思恭.秘传证治要诀[M].北京：中国中医药出版社,1998,79.
[6]明·秦景明.症因脉治[M].上海：上海科学技术出版社,1990,145.
[7]清·叶天士.临证指南医案[M].北京：华夏出版社,1995,226-227.
[8]清·陈修园.时方妙用[M].福州：福建科学技术出版社,1986,49-50.
[9]清·何梦瑶.医碥[M].上海：上海科学技术出版社,1992,95.
[10]隋·巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社,1997,18-75.
[11]唐·王焘.外台秘要精华本[M].沈阳：辽宁科学技术出版社,1998,54-87.
[12]元·朱震亨.丹溪心法[M].北京：人民卫生出版社,2005,27-28.
[13]明·王肯堂.证治准绳[M]北京：人民卫生出版社,1991,99.
[14]清·唐容川.血证论[M].北京：中国中医药出版社,1996,147.
[15]汉·张仲景.金匮要略[M].北京：人民卫生出版社,2005,44.
[16]清·李用粹.证治汇补[M].上海：上海卫生出版社,1958,278.
[17]明·楼英.医学纲目[M].北京：中国中医药出版社,1996,604.
[18]明·李中梓.医宗必读[M].北京：中国中医药出版社,1 999,261.
[19]清·吴谦.医宗金鉴精选[M].北京：科学技术文献出版社,1996,53.
[20]元·朱丹溪.金匮钩玄[M].北京：人民卫生出版社,1980,15.
[21]清·陈梦雷.古今图书集成医部全录·诸疾(上)[M]北京：人民卫生出版社,1962,1394-1399.
[1]代晓光,陈晶,郭欣,等.化痰法治疗哮喘的研究现状及评价[J].中医药信息,2005,22(6)：7-9.
[2]冯新格.吴银根妙用药对治疗支气管哮喘[J].浙江中医杂志,1999,34(12)：507-508.
[3]王江.治疗哮喘浅谈[J].河南中医,2006,26(12)：32-33.
[4]赵宝林.哮喘病因病机及经方认识的探讨[J].中医药临床杂志,2006,1 8(1)：85-87.
[5]孙继铭.从内风论治支气管哮喘90例分析[J].实用中医内科杂志,2003,17(5)：414
[6]王鹏.中医哮病学[M].北京：中国医药科技出版社,2002,10.
[7]吴银根,于素霞,张惠勇,等.咳喘落治疗175例哮喘临床总结[J].上海中医药杂志,2000,34(9)：20.
[8]聂广.肺朝百脉及其临床意义[J].贵阳中医学院学报,1989,11(1)：7-8.
[9]洪广祥.支气管哮喘病科研思路方法刍议[J].江西中医药,1991,22(2)：11-14.
[10]刘莎,卢薇.浅谈支气管哮喘的中医药研究[J].光明中医,2009,24(1)：171.
[11]金小晶,张文博.张明德谈哮喘“夙根”[J].时珍国医国药,2002,13(12)：756.
[12]刘仁慧.哮喘缓解期治疗宜肺脾肾三脏并补[J].现代中西医结合杂志,2004,13(24)：3354.
[13]袁启福,汤淑兰.祛风平喘汤治疗儿童哮喘发作50例[J].湖南中医学院学报,1995,15(1)：24-25.
[14]张洪春,晁恩祥.疏风解痉法治疗过敏性支气管哮喘的临床研究[J].中国中医急症,1998,7(2)：54-60.
[15]于作洋.刘弼臣教授治疗小儿哮喘的经验[J].山西中医,1998,14(4)：6-7.
[16]熊耀,俞冰.哮喘临床研究进展[J].浙江中医学院学报,2001,25(3)：5-7.
[17]王长洪.董建华治疗哮喘的经验[J].辽宁中医杂志,1999,26(12)：531-532.
[18]张占伟,王春玲,王鹏,等.温阳化瘀法在治疗哮喘中的应用[J].中医药研究,2000,16(8)：55-57.
[19]毛玉燕.钱育寿治疗小儿哮喘的经验[J].河北中医,2000,22(3)：1-2.
[20]刘玉山,张爱华,王玉民.射干麻黄汤加味治疗小儿哮喘103例疗效观察[J].河北中医,2001,23(6)：4.
[21]张天嵩,吴红梅.吴银根温阳法分期治疗哮喘学术特色探析[J].中医函授通讯,1999,18(6)：3-5.
[22]张穗,张小鹰,赵前江.倪珠英论治小儿哮喘的经验[J].湖北中医学院院报,2000,2(2)：36.
[23]杨华萃,许尤佳.中西医结合治疗小儿哮喘的远期疗效观察[J].湖北中医杂志,2000,22(8)：17-18.
[24]廖世才.小儿哮喘活血化瘀法治疗体会[J].江西中医药,1997,28(6)：33-34.
[25]陈黎明,张俐.从瘀血论治哮喘机理探讨[J].国医论坛,1999,14(2)：17.
[26]王明明,汪受传.玉屏风散预防小儿哮喘临床效果及机理探讨[J].时珍国医国药,2001,12(5)：457-458.
[27]杨定保.小儿哮喘辨治三法[J].湖北中医杂志,2001,23(4)：21.
[28]魏伟,吴成.中医对哮喘病因病机及发作期冷热分型认识初探[J].现代中西医结合杂志,2004,13(11)：1444.
[29]王爱明.中西医结合防治小儿哮喘64例疗效观察[J].江苏中医,2000,21(3)：22-23.
[30]罗玉华.小儿哮喘的中医辨证治疗[J].四川中医,2002,20(1)：17.
[31]张成博.哮喘病分期及治疗构想[J].山东中医杂志,2005,24(9)：519-520.
[32]田德禄主编.中医内科学[M].北京：人民卫生出版社,2002,69-72.
[1]张洪春,晁恩祥.疏风解痉法治疗过敏性支气管哮喘的临床研究.中国中医急症,1998,7(2)：54-58.
[2]闫建纯.中药颗粒剂麻杏祛风定喘方治疗幼儿哮喘[J].湖北中医杂志,2006,28(8)：26.
[3]付伟.中药治疗支气管哮喘50例体会[J].哈尔滨医药,2005,25(3)：56.
[4]武维屏.调肝理肺法治疗哮喘174例小结[J].北京中医学院学报,1990,13(4)：55.
[5]董振华,季元,范爱平.祝谌予治疗哮喘的经验[J].浙江中医杂志,1994,29(1)：19.
[6]武振东,潘成轩,秦立云.血府逐瘀汤为主治疗支气管哮喘61例观察[J].河南中医,2000,20(6)：43.
[7]李庆林.桃红四物汤加减治疗哮喘31例[J].河南中医,2005,25(3)：66.
[8]陈茂业.金芪固本汤治疗支气管哮喘缓解期46例临床观察[J].云南中医中药杂志,2007,28(6)： 24.
[9]单昌涛.加味补中益气汤治疗支气管哮喘缓解期的临床观察[J].河北中医,2005,27(8)：604.
[10]黎经兰.补肾纳气法治疗小儿支气管哮喘38例[J].中医研究,2005,18(1)：39-40.
[11]王德玉,柴可群.咳喘从肝论治[J].浙江中医学院学报,1993，17(4)：10.
[12]王利,车戬,朴龙华.调肝理肺汤治疗支气管哮喘急性发作期的临床研究[J].辽宁中医杂志,2003,30(6)：465-466.
[13]史锁芳.曹世宏治支气管哮喘经验[J].江西中医药,1998,29(6)：76.
[14]刘自力,张庆荣,吴兆利.论脾虚为哮喘宿根[J].中医药学刊,2006,24(2)：294-295.
[15]周虎.和胃降逆法治疗夜间哮喘临床观察[J].中医杂志,1993,34(6)：359.
[16]蔡润清,吴伟平.支气管哮喘缓解期从脾论治80例临床探讨[J].贵阳中医学院学报,2007,29(2)：29-30.
[17]张洁,施光其.黄芪六君子汤治疗哮喘缓解期85例临床观察[J].山东中医杂志,2004,23(4)：204-205.
[18]翟乃会,武翠风.通腑泄肺法治疗顽固性哮喘53例[J].陕西中医,1999,20(10)：466.
[19]李家榕.审证求因治咳喘一张鸿祥经验谈[J].上海中医药杂志,1996,30(4)： 24.
[20]苏惠萍.通腑法治疗哮喘发作期的临床应用[J].北京中医药大学学报,1995,18(5)：64.
[21]龙学明,唐耀平,黄洁,等.补肺片对支气管哮喘缓解期患者CD4+、CD8+及IgE影响的临床研究[J].新中医,2007,39(5)：27-28.
[22]王晓玫,李忠学.固金止喘汤治疗支气管哮喘缓解期35例的疗效分析[J].中华实用中西医杂志,2006,19(6)：661-662.
[23]刘勤建.玉屏风散合参蛤散治疗缓解期哮喘疗效观察[J].中国中医基础医学杂志,2002,8(12)：45-47.
[24]张锦珠,王健民.补肺益肾汤治疗支气管哮喘32例[J].陕西中医,1995,16(10)：439.
[25]吴彬,俞建,王营,等.补肾中药对哮喘缓解期患儿Th1/Th2平衡的影响[J].中国中西医结合杂志,2007,27(4)：120-122.
[26]刘小虹,廖慧丽.补肾祛邪法治疗哮喘的临床研究[J].中医药学刊,2002,20(5)：697-700.
[27]李容娟,固肾纳气汤治疗肾虚型哮喘缓解期42例疗效观察[J].右江民族医学院学报,1997,19(3)：449-500.
[28]刘贵云,向华林,米仁贤,等.治喘伏帖灵治疗小儿哮喘139例疗效观察[J].中医杂志,1999,40(8)：474.
[29]刘霞秋,徐京生,崔锐.交九散贴敷治疗支气管哮喘的临床观察[J].中国中西医结合杂志,1996,16(5)：297.
[30]姜静,尚宁,范欣生.中药辛夷雾化吸入治疗支气管哮喘[J].临床肺科杂志,2001,6(2)：17.
[31]张莉,周勇,王旭丹,等.芩夏止哮颗粒对哮喘小鼠T细胞活化和细胞因子水平的影响[J].中药药理与临床,2002,18(1)：21-23.
[32]倪力强,张宁霞,童瑶,等.小青龙汤对哮喘大鼠Thl/Th2型细胞因子水平的影响[J].辽宁中医杂志,2003,30(9)：703-704.
[33]谭素娟,艾华.射干麻黄汤化裁方抗过敏性支气管哮喘的实验研究[J].中医杂志,2000,41(5)：282.
[34]谢瑾玉,董竞成.补肾益气中药仙灵脾和黄芪对哮喘大鼠TNF-α和NF-κB的影响[J].中国中西医结合杂志,2006,26(8)：723-724.
[35]张弦,王强,孙增涛.补肺方对缓解期哮喘豚鼠气道重塑作用机制的研究[J].江西中医学院学报,2009,21(2)：57-58.
[36]刘小虹,廖慧丽.射麻止喘液对哮喘模型大鼠环核甘酸变化的影响[J].广东中医药大 学学报,2001,18(4)：339-340.
[37]赵琰,屈会化,张晗睿,等.加味三拗汤平喘作用及对肺功能影响的实验研究[J].北京中医药大学学报,2009,32(1)：21-24.
[38]黄乐珊,郑师明.截喘汤对哮喘模型小鼠外周血浆IL-5、TNF-α及Eotaxin的影响[J].中国药房,2007,18(15)：1134-1135.
[39]吴银根,王宏长,张惠永,等.温阳抗寒合剂对实验性哮喘动物模型的研究[J].中国中医基础杂志,1996,2(2)：22.
[40]崔红生,黄启福,武维屏,等.哮喘宁煎剂对哮喘豚鼠模型气道EOS浸润的影响[J].中华结核和呼吸杂志,1992,22(8)：495.
[41]王力宁,李伟伟,李伟芳,等.六味地黄丸协同必可酮对致敏豚鼠气道反应性及血嗜酸细胞的影响[J].广西中医药,2001,24(6)：51.
[42]李寅超,赵宜红,薛敬礼,等.辛夷挥发油对哮喘豚鼠嗜酸性粒细胞影响的实验研究[J].现代预防医学,2006,33(8)：1338-1341.
[43]邬继红,马惠芳,袁红,等.不同针刺频度对致敏豚鼠血清总IgE影响的实验研究[J].针刺研究,2006：31(3)：153-155.
[44]司小兵,陈淑彦.“咳喘宁”贴膏对支气管哮喘模型大鼠血清IL-8及TNF-α的影响[J].甘肃中医学院学报,2006,23(6)：6-7.
[45]刘世琼,张全爱.咳喘灵贴膏贴敷穴位治疗豚鼠哮喘的实验研究[J].中医药学刊,2004,22(4)：620-621.
[1]董滟,雷敏.中医药治疗支气管哮喘的优势评析[J].四川中医,2006,24(12)：21-23.
[2]武维屏.激素依赖性哮喘的中医治疗浅述[J].北京中医药大学学报,1997,20(1)： 58.
[3]许德金,叶丽红.活血化瘀药防治支气管哮喘的研究进展[J].微循环技术杂志,1996,3163.
[4]方文贤.医用中药药理学[M].北京：人民卫生出版社,1998,18.
[1]王建华,张永祥,周文霞主编.中药药理与临床研究进展[M].北京：人民卫生出版社,2006：386.
[2]陈慧梅.代谢组学及研究方法和应用[J].肾脏病与透析肾移植杂志,2005,14(1)：59-63.
[3]Gennan JB,Bauman DE,Burrrin DG,et al.Metabolomics in the opening decade of the 21st century:building the roads to individualiazed health[J].Jnutn,2004,134 (10):27-29.
[4]邓海山,段金廒,尚尔鑫,等.代谢组学的研究现状及其在方剂量效关系中的应用[J].国际药学研兖杂志,2009,36(3)：199.
[5]魏聪.代谢组学及其在中医药现代化研究中的应用进展[J].疑难病杂志,2009,(8)11：698.
[6]许国旺,路鑫,杨胜利.代谢组学研究进展[J].中国医学科学院学报.2007,29(6)：701-711.
[7]罗和古,丁杰,岳广欣,等.大鼠肝郁脾虚证的代谢组学研究[J].中西医结合学报,2007,5(3)：307-313.
[8]高岗,杨根金,娄子洋.肾虚证大鼠尿液的核磁共振谱代谢组学研究[J]。第二军医大学学报,2009,30(5)：5665-5668.
[9]刘树民,卢芳,王喜军,等.基于代谢组学的热病证候模型评价方法研究[J].中国药理学通报,2009,25(4)：549-551.
[10]Chen MJ, Zhao LP.Jia W. Metahonomicon study on the biochemical profiles of hydroeoaisone-inducedmodel animal model[J].Journal of Proteme Research,2005,4(6): 2391-2396.
[11]严蓓,阿基业,郝海平,等.心血瘀阻与气阴两虚证心肌缺血大鼠模型的代谢组学表征与辨识[J].中国科学c辑：生命科学,2008,38(12)：1143-1151.
[12]王广基,阿基业,严培,等.代谢组学研究冠心病中医分型的体内物质基础[J].世界科学技术-中医药现代化,2009,11(1)：127-133.
[13]郑海生,蒋健,贾伟,等.慢性心力衰竭肾阳虚患者代谢组学研究[J].中华中医药杂志,2010,25(2)：198-201.
[14]吕爱平.类风湿性关节炎中医证候分类的系统生物学基础[J].世界科学技术-中医药现代化,2007,9(1)：94-97.
[15]董飞侠,黄迪,何立群,等.Ⅲ期慢性肾病肾阳虚证患者尿液代谢组学特征的研究[J].中华中医药杂志,2008,23(12)：1109-1113.
[16]杨松滨,李听,苏明明,等.膝骨关节炎患者尿液代谢谱与中医证候的相关性研究[J].上海中医药大学学报,2009,23(1)：33-37.
[17]王喜军,孙文军,孙晖,等.CCI诱导大鼠肝损伤模型的代谢组学及茵陈蒿汤的干预作用研究[J].世界科学技术—中医药现代化,2006,8(6)：101-106.
[18]黄玉荣,魏广力,龙红.钩藤多动合剂的药效作用及用代谢组学方法研究其生化机制[J].中草药,2005,36(3)：398-402.
[19]周明眉,刘平,贾伟.基于代谢网络变化的中药整体效应评价方法研究[J].世界科学技术-中医药现代化,2006,8(6)：113-119.
[20]邱云平,苏明明,吴大正,等.金复康对大鼠大肠癌癌前病变的改善作用及尿液代谢物研究[J].中国中药杂志,2008,33(22)：2653-2657.
[21]Li FM,Lu XM,Liu HP,et al.A pharmaco-metabonomic study basis and metabolic effects of Epimedium brevleomum Maxim.on hydroeortisone-induced rat using UPLC-MS[J]. Biomed Chromatogr,2007,21(4):397-405.
[22]蒋宁,周文霞,张永样.应用代谢组学方法研究比较六味及八味地黄汤的作用机理[J].中药药理与临床,2007,23(5)：45.
[23]Minjun Chen,Liping Zhao,Weijia,et al.Metabonomic study on the biochemical profile of a hydrocortisone induced animal model[J].J Proteome Res,2005,4(6):2391-2396.
[24]陆益红,王广基,黄青,等.自发性高血压大鼠血浆代谢组学研究及人参总皂苷作用机制初探[J].中国天然药物,2007,11(6)：443-447.
[25]薛骞.代谢组学技术：中医药发展的重大契机[J].中华中医药学刊,2008,26(1)：176-177.
[26]赵剑宇,颜贤忠,彭双清.利用代谢组学技术研究中药关木通的肾毒性作用[J].世界科学技术一中医药现代化,2007,9(5)：54.
[27]李建新,华嘉,何翠翠.中药毒性的代谢组学研究(Ⅰ)雷公藤甲素的肾脏毒性[J].亚太 传统医药,2007,3(7)：4145.
[28]张晓字,吴惠丰,裴奉套,等.核磁共振技术结合模式识别对中药马兜铃酸哑急性生化效应的研究[J].高等学校化学学报,2005,26(6)：991-996.
[29]蒋怀周,鲍远程.代谢组学应用于中医药研究的思考[J].中医药学报,2010,38(4)：63-67.
[30]曾瑞峰,李俊.代谢组学方法及其在中医药研究的现状与展望[J].中国中医药现代远程教育,2010,8(17)：205-206.
[1]清·雷丰.时病论[M].北京：人民卫生出版社,2008.136.
[2]周悦.中医药治疗哮喘的优势浅谈[J].江西中医药,2009,4 0(320)：9-10.
[1]刘素芝,刘玉丽,曹国龙,等.哮喘动物模型免疫炎症反应发生验证的要点[J].中国组织工程研究与临床康复,2007,2(29)：5814.
[2]何会霞,李自红.支气管哮喘实验动物模型的研究进展[J].中国老年学杂志,2008,23(10)：2074.
[3]颜晓燕,董志远.哮喘动物模型研究现状[J].成都医学院学报,2007,2(2)：157.
[4]Obiefuna P. C. M, Batra V. K, Nadeem A, Borron Pet al.Novel Adenosine Receptor Antagonist,L-97-1[3-[2-(4-Aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-e thyl}-l-propyl-3,7-dihydro-purine-2,6-dione], Reduces Allergic Responses to House Dust Mite in an Allergic Rabbit Model of Asthma[J]. Mustafa J Pharmacol Exp Ther.2005 October 315(1): 329-336.
[5]刘学.血液中嗜酸性粒细胞与气道高反应性关系分析研究[J],安庆医学,2004,25(3)：12-13.
[6]唐美仪,毛新,姜运良.新生家兔白细胞系统数量和形态的日龄相关性变化[J].曲阜师范大学学报,1991,17(3)：66-70.
[7]中华医学会呼吸病学分会.支气管肺泡灌洗液细胞学检测技术规范(草案)[J].中华结核和呼吸杂志,2002,25(7)：390-391.
[8]Hall JC. Glycine. J Parenter Enterol Nutri,1998,22(6):393-398.
[9]Grotz MR, Pape HC, Van Griensven M, et al. Glycine reduces thein flammatory response and organ damage in a two-hit sepsis modelin rats. Shock,2001,16:116-121.
[10]Legendre P.The glycinergic inhibitory synapse[J].Cell Mol Life Sci,2001,58(5-6):76-93.
[11]冯端兴,叶贤伟,张湘燕,等.132—肾上腺素能受体基因多态性与支气管哮喘的研究[J].现代临床医学生物工程学杂志,2004,10(1)：5-7.
[12]刘超,郭贵龙,姚榛祥.甘氨酸对腹腔感染小鼠急性肺损伤的作用[J].山西临床医药杂志,2001,10(5)：331-333.